ANIX vs. MIST, PRPH, ACRS, ETON, CLSD, ONCY, SPRO, CMRX, QTTB, and ORMP
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Milestone Pharmaceuticals (MIST), ProPhase Labs (PRPH), Aclaris Therapeutics (ACRS), Eton Pharmaceuticals (ETON), Clearside Biomedical (CLSD), Oncolytics Biotech (ONCY), Spero Therapeutics (SPRO), Chimerix (CMRX), Q32 Bio (QTTB), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Anixa Biosciences has lower revenue, but higher earnings than Milestone Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anixa Biosciences had 7 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 7 mentions for Anixa Biosciences and 0 mentions for Milestone Pharmaceuticals. Anixa Biosciences' average media sentiment score of 0.00 beat Milestone Pharmaceuticals' score of -0.63 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Milestone Pharmaceuticals has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Milestone Pharmaceuticals received 57 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 67.57% of users gave Milestone Pharmaceuticals an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Milestone Pharmaceuticals presently has a consensus target price of $10.75, indicating a potential upside of 528.69%. Anixa Biosciences has a consensus target price of $12.00, indicating a potential upside of 300.00%. Given Anixa Biosciences' higher probable upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Anixa Biosciences.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 10.4% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Milestone Pharmaceuticals' return on equity of -44.09% beat Anixa Biosciences' return on equity.
Summary
Milestone Pharmaceuticals beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
